This could lead to better blood sugar control, fewer diabetes-related complications, and lower long-term healthcare costs for both patients and the healthcare system
FDA approves new medication for chronic weight management, FDA (2023) Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review, NIH (2022) Mounjaro- tirzepatide injection, Eli Lilly (2023) Mounjarotm (tirzepatide) injection, FDA (2022) Lillys tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks, Eli Lilly (2023) How to use Mounjaro, Eli Lilly (2023) Mounjaro dietary instructions, CNMRI (2023) Weekly exercise targets, American Diabetes Association (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
(PubMed) Kennedy DO, Veasey R, Watson A, et al
It clarifies
This allows the body to reset its set pointthe weight the body naturally tries to maintain
The bill passed committee 13-2 and now heads to the full House for consideration